Arcutis Announces Updates to its Executive Team

WESTLAKE VILLAGE, Calif., March 26, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced several executive leadership updates, primarily as part of its continued preparations for the eventual launch and commercialization of its pipeline products.

Click to view original post